A detailed history of Gts Securities LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Gts Securities LLC holds 35,218 shares of CVAC stock, worth $89,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,218
Holding current value
$89,453
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.74 - $3.79 $96,497 - $133,476
35,218 New
35,218 $103,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $476M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.